Search

Your search keyword '"Forconi, Francesco"' showing total 92 results

Search Constraints

Start Over You searched for: Author "Forconi, Francesco" Remove constraint Author: "Forconi, Francesco" Publisher elsevier inc. Remove constraint Publisher: elsevier inc.
92 results on '"Forconi, Francesco"'

Search Results

2. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib

3. High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL

6. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

8. IL-4 enhances expression and function of surface IgM in CLL cells

11. The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model

12. DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features

14. CLL-638 Latest Results From an Ongoing Firstin-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies

15. Latest Results From an Ongoing First-in-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies

16. Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

17. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome

20. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia

21. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia

22. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation

23. The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma

24. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome

25. Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia

28. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior

29. MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

35. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia

36. International Prognostic Score (IPS-A) for Patients with Early Stage Chronic Lymphocytic Leukemia

39. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia

40. Acalabrutinib in Patients (pts) with Waldenström Macroglobulinemia (WM)

44. Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

45. BRAF and BIRC3 Mutations Stratify a Poor Prognostic Subgroup in FCR Treated Chronic Lymphocytic Leukemia

47. Mutations of BRAF and BIRC3 Identify a Subgroup of Chronic Lymphocytic Leukemia with Very Poor Prognosis upon FCR Treatment

Catalog

Books, media, physical & digital resources